Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis

Table 1 Characteristics of studies included in the qualitative systemic review

First author	Year	Country	Participants	Race/ethnicity	Study design	Year range	Treatment	ROBINS-I^d	Follow-up (PT/no PT)(years)	Primary outcome in the original study
van Sprundel [17]	2005	The Netherlands (M)	148 BRCA1/2 carriers	NR	RC	~ 2003	CRRM	Moderate	Mean 3.5 (3.4/3.1)	CBC, BCSS, OS, DMR
Kiely [11]	2009	Australia (M)^a	1018 BRCA1/2 carriers from high-risk families	Caucasian 95% Asian 1% Other 2% Unknown 2%	RC	1997–2008	CRRM	Serious	Median 11.1 (8/11.7)	OS, CBC
Evans [10]	2013	The UK (M)	698 BRCA1/2 carriers	NR	PC	1985–2010	CRRM	Moderate	Median 8.8/7.3	CBC, OS
Metcalfe [18]	2014	Canada (M)	390 patients^c	NR	RC	1975–2008	CRRM	Moderate	Median 9.7/8.6	CBC, OS
Heemskerk-Gerritsen [19]	2015	The Netherlands (M)^b	583 BRCA1/2 carriers	NR	PC	1980–2011	CRRM	Moderate	Median 14.3	CBC, OS
Fachinetti [35]	2019	Italy (S)	88 BRCA1/2 carriers	NR	RC	2006–2016	CRRM	NA	Median 11.4 (11.4/11.3)	CBC, OS
Evron [36]	2019	Isreal (M)	162 BRCA1/2 carriers	NR	PC	2008–2017	CPI	Moderate	Median 10	CBC, OS

RC retrospective cohort study, PC prospective cohort study, CBC contralateral breast cancer, BCSS breast-cancer specific survival, OS overall survival, DMR distant metastatic recurrence, M multicenter study, S single-center study, NR Not reported, NA Not applicable
^aPatients were enrolled in the research program called kConFab (Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer)
^bMembers of breast and/or ovarian cancer centers in the HEBON study (nationwide Dutch study on risk assessment and gene–environment interactions)
^c336 patients were proved to be BRCA1/2 carriers, 54 were not tested but from family with a BRCA mutation
^dSpecific assessment for each signal question in the ROBINS-I tool see: Additional file 1: Method S2

ISSN: 1475-2867